top of page
toraih resized and compressed.jpg

Eman Toraih, MD, PhD

Sex differences in obesity pathophysiology and GLP-1 receptor agonist treatment response

 

Dr. Toraih's research program utilizes cutting-edge genomic technologies, advanced bioinformatics, and innovative AI approaches to investigate sex differences in obesity susceptibility, fat distribution, and response to GLP-1 receptor agonist (GLP-1Ra) treatment. The basic science component of the program focuses on identifying sex-specific genetic variants and biological pathways associated with central and peripheral obesity using genome-wide association studies and integrative bioinformatics analyses. The translational branch aims to assess the clinical impact of sex-specific polygenic risk scores on GLP-1Ra treatment outcomes in men and women with obesity.

The long-term goal of Dr. Toraih's research project is to develop personalized, sex-specific strategies for obesity risk assessment and treatment optimization. This work aims to improve patient outcomes and reduce healthcare disparities by tailoring obesity management approaches to the unique biological needs of both men and women.

bottom of page